
INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment
INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review p...
